JP2023510350A5 - - Google Patents

Info

Publication number
JP2023510350A5
JP2023510350A5 JP2022542336A JP2022542336A JP2023510350A5 JP 2023510350 A5 JP2023510350 A5 JP 2023510350A5 JP 2022542336 A JP2022542336 A JP 2022542336A JP 2022542336 A JP2022542336 A JP 2022542336A JP 2023510350 A5 JP2023510350 A5 JP 2023510350A5
Authority
JP
Japan
Prior art keywords
cdr
seq
complex according
exon
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022542336A
Other languages
English (en)
Japanese (ja)
Other versions
JP7780691B2 (ja
JP2023510350A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012756 external-priority patent/WO2021142307A1/en
Publication of JP2023510350A publication Critical patent/JP2023510350A/ja
Publication of JP2023510350A5 publication Critical patent/JP2023510350A5/ja
Priority to JP2025172493A priority Critical patent/JP2026012197A/ja
Application granted granted Critical
Publication of JP7780691B2 publication Critical patent/JP7780691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022542336A 2020-01-10 2021-01-08 ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 Active JP7780691B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025172493A JP2026012197A (ja) 2020-01-10 2025-10-14 ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202062959796P 2020-01-10 2020-01-10
US62/959,796 2020-01-10
US202062965748P 2020-01-24 2020-01-24
US62/965,748 2020-01-24
US202062968443P 2020-01-31 2020-01-31
US62/968,443 2020-01-31
US202062980874P 2020-02-24 2020-02-24
US62/980,874 2020-02-24
US202063055537P 2020-07-23 2020-07-23
US63/055,537 2020-07-23
US202063069066P 2020-08-23 2020-08-23
US63/069,066 2020-08-23
US202063132929P 2020-12-31 2020-12-31
US63/132,929 2020-12-31
PCT/US2021/012756 WO2021142307A1 (en) 2020-01-10 2021-01-08 Muscle targeting complexes and uses thereof for treating dystrophinopathies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025172493A Division JP2026012197A (ja) 2020-01-10 2025-10-14 ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2023510350A JP2023510350A (ja) 2023-03-13
JP2023510350A5 true JP2023510350A5 (cg-RX-API-DMAC7.html) 2024-01-22
JP7780691B2 JP7780691B2 (ja) 2025-12-05

Family

ID=76788858

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022542336A Active JP7780691B2 (ja) 2020-01-10 2021-01-08 ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
JP2025172493A Pending JP2026012197A (ja) 2020-01-10 2025-10-14 ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025172493A Pending JP2026012197A (ja) 2020-01-10 2025-10-14 ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用

Country Status (10)

Country Link
US (1) US20230111212A1 (cg-RX-API-DMAC7.html)
EP (1) EP4087878A4 (cg-RX-API-DMAC7.html)
JP (2) JP7780691B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220125802A (cg-RX-API-DMAC7.html)
CN (1) CN115335401A (cg-RX-API-DMAC7.html)
AU (1) AU2021205346A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022013572A2 (cg-RX-API-DMAC7.html)
IL (1) IL294478A (cg-RX-API-DMAC7.html)
MX (1) MX2022008540A (cg-RX-API-DMAC7.html)
WO (1) WO2021142307A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020219820A1 (en) 2019-04-25 2020-10-29 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
US20230111212A1 (en) * 2020-01-10 2023-04-13 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP4087653A4 (en) * 2020-01-10 2024-06-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
MX2023000984A (es) * 2020-07-23 2023-05-03 Dyne Therapeutics Inc Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias.
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
JPWO2022270585A1 (cg-RX-API-DMAC7.html) 2021-06-23 2022-12-29
JP2024525613A (ja) * 2021-07-09 2024-07-12 ダイン セラピューティクス,インコーポレーテッド 筋標的化複合体およびジストロフィノパチーを処置するためのその使用
CA3226301A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US20240318176A1 (en) * 2021-07-09 2024-09-26 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023026994A1 (ja) * 2021-08-21 2023-03-02 武田薬品工業株式会社 ヒトトランスフェリンレセプター結合ペプチド-薬物コンジュゲート
EP4395829A1 (en) * 2021-09-01 2024-07-10 Entrada Therapeutics, Inc. Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
EP4395831A1 (en) * 2021-09-01 2024-07-10 Entrada Therapeutics, Inc. Compositions and methods for skipping exon 45 in duchenne muscular dystrophy
IL311507A (en) * 2021-09-16 2024-05-01 Dyne Therapeutics Inc Dosing of muscle targeting complexes for the treatment of dystrophinopathy
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
JP2026503873A (ja) * 2022-10-31 2026-02-02 ダイン セラピューティクス,インコーポレーテッド Dmd遺伝子のエクソン45をスキップするための筋肉標的化複合体およびその使用
JP2026516311A (ja) 2023-04-24 2026-05-21 バイオマリン ファーマシューティカル インコーポレイテッド Stxbp1障害を治療するための組成物および方法
CN120648680A (zh) * 2024-03-15 2025-09-16 迦进生物医药(上海)有限公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的药物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
ES2283759T3 (es) * 2002-01-18 2007-11-01 Pierre Fabre Medicament Anticuerpos anti-igf-ir y sus aplicaciones.
EP2427554B1 (en) * 2009-05-08 2016-11-16 CuRNA, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
EP2658574A4 (en) * 2010-12-30 2014-03-12 Cedars Sinai Medical Center NANOBIOPOLYMER COMPOSITIONS BASED ON POLYEPELIC ACID BASE AND METHOD FOR THE TREATMENT OF CANCER
CN104520324A (zh) * 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
JP6779876B2 (ja) * 2014-11-19 2020-11-04 ジェネンテック, インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
KR20240172236A (ko) * 2017-01-06 2024-12-09 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
CN118638787A (zh) * 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
IL312067B2 (en) * 2018-12-21 2025-08-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof
WO2021142331A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
JP7858532B2 (ja) * 2020-01-10 2026-05-14 ダイン セラピューティクス,インコーポレーテッド 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用
WO2021142260A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of acvr1
WO2021142269A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
CN115427448A (zh) * 2020-01-10 2022-12-02 达因疗法公司 肌肉靶向复合物及其用途
EP4087653A4 (en) * 2020-01-10 2024-06-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20230111212A1 (en) * 2020-01-10 2023-04-13 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CN122124274A (zh) * 2020-01-10 2026-06-02 达因疗法公司 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
WO2021142217A1 (en) * 2020-01-10 2021-07-15 Dyne Thereapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of milck1
IL295022A (en) * 2020-01-31 2022-09-01 Dyne Therapeutics Inc Antibody against transferrin receptor and uses thereof
JPWO2022270585A1 (cg-RX-API-DMAC7.html) * 2021-06-23 2022-12-29

Similar Documents

Publication Publication Date Title
JP2024527362A5 (cg-RX-API-DMAC7.html)
JP2023535073A5 (cg-RX-API-DMAC7.html)
JP2024525610A5 (cg-RX-API-DMAC7.html)
JP2023509793A5 (cg-RX-API-DMAC7.html)
JP2021532831A5 (cg-RX-API-DMAC7.html)
JP2024525611A5 (cg-RX-API-DMAC7.html)
JP2024525612A5 (cg-RX-API-DMAC7.html)
JP2023512441A5 (cg-RX-API-DMAC7.html)
Hudson Recombinant antibody fragments
JP6420813B2 (ja) 抗シュードモナス属(Pseudomonas)Psl結合分子およびその使用
JP2024525613A5 (cg-RX-API-DMAC7.html)
Beiboer et al. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent
JP2023512442A5 (cg-RX-API-DMAC7.html)
JP2023511774A5 (cg-RX-API-DMAC7.html)
JP2024540199A5 (cg-RX-API-DMAC7.html)
JP2023510351A5 (cg-RX-API-DMAC7.html)
JP7663977B2 (ja) 抗pd―l1抗体およびその用途
IL309936A (en) Muscle targeting complexes and formulations for treating dystrophinopathies
JP2024524222A5 (cg-RX-API-DMAC7.html)
JP2023549537A5 (cg-RX-API-DMAC7.html)
JP2011509245A5 (cg-RX-API-DMAC7.html)
JP2008542278A5 (cg-RX-API-DMAC7.html)
AU2016304060A1 (en) Antibody against glypican-3 and application thereof
JP2010511388A5 (cg-RX-API-DMAC7.html)
RU2009123409A (ru) Новые антипролиферативные антитела